Medicine and Dentistry
Dosimetry
100%
Absorbed Dose
86%
Therapeutic Procedure
55%
Radioimmunotherapy
52%
Radioisotope
51%
Prostate Cancer
44%
Extracorporeal
44%
Patient
38%
Radionuclide Therapy
35%
Single-Photon Emission Computed Tomography
34%
Immunoabsorption
33%
Organ
29%
Technetium-99
28%
Iodine 125
26%
Injection
24%
Iodine 131
24%
Blood
24%
Cells
21%
Testes
19%
Irradiation
19%
Combination Therapy
17%
Particle Therapy
16%
Bone Marrow
16%
Xenograft
16%
Liver
15%
Monte Carlo Method
14%
Nuclear Medicine
13%
Therapeutics
13%
Development
12%
Measurement
12%
Positron Emission Tomography
12%
B-Cell Lymphoma
12%
Platelet
11%
Drug Megadose
11%
Nanoparticle
10%
Clinical Dosimetry
10%
Human
10%
Breast Cancer
9%
Ex Vivo
8%
Americium 241
8%
Radiosensitivity
7%
Iodine 124
7%
Quantitative Imaging
7%
Positron Emission Tomography - Magnetic Resonance Imaging
7%
Nanoparticle
7%
Treatment Planning
6%
Neuroendocrine Tumor
6%
Metabolic Rate
6%
Carcinoembryonic Antigen
6%
Tumor Cell
6%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
84%
Radioisotope
68%
Lutetium 177
59%
Dosimetry
59%
Indium 111
46%
Antibodies
28%
Technetium 99m
25%
Peptide
23%
Radiopharmaceutical Agent
22%
Biodistribution
21%
Receptor
21%
Yttrium 90
21%
Pharmacokinetics
20%
Autoradiography
18%
B Cell Lymphoma
17%
Iodine-131
17%
Malignant Neoplasm
17%
Nephrotoxicity
17%
Toxicity
14%
Colon Carcinoma
13%
Gamma Ray
11%
Mouse Model
11%
Rat Model
10%
Endotoxin
10%
Prostate Cancer
10%
Recombinant
9%
Antioxidant
9%
Castration Resistant Prostate Cancer
9%
Radioligand
8%
Irradiation
7%
Primate
7%
Kidney Injury
7%
Superparamagnetic Iron Oxide Nanoparticle
7%
Blood Toxicity
7%
Nanoparticle
7%
Chemotherapy
6%
Actinium 225
5%
Inhalation
5%
Bear
5%
Glucose
5%
Prostate Specific Antigen
5%
Cell Death
5%
Sulfur 35
5%
Methoxy Isobutyl Isonitrile Technetium Tc 99m
5%
Maximum Tolerated Dose
5%
Ibritumomab Tiuxetan
5%
Alpha 1 Microglobulin
5%
Synapsin I
5%
Polyethylene Terephthalate
5%
Monoclonal Antibody
5%
